
|Articles|May 1, 2004
Long-term outcome of juvenile dermatomyositis rests on early treatment with immunosuppresants
Washington -Timely diagnosis of juvenile dermatomyositis is critical because early, aggressive management with immunosuppressive agents, even for patients with amyopathic disease, is the best method for preventing calcinosis, which is a source of significant morbidity for these children, said Amy S. Paller, M.D., at the annual meeting of the American Academy of Dermatology.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clinicians Weigh Topical Sequencing and Escalation in Complex Atopic Dermatitis Cases
2
Common Mistakes in Managing Hair Loss and Pigmentary Disorders
3
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
4
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
5











